merck
Pharma

Merck sees ‘pretty consistent’ data in sac-TMT’s 1st global ph. 3

The endometrial cancer data gave sac-TMT its first positive global phase 3 readout out of 18 trials that Merck has launched for the TROP2 ADC.
Angus Liu Oct 26, 2026 11:30am
Soccer ball flying into a net scoring a goal

Pfizer’s Talzenna combo moves up treatment line with FDA nod

Oct 26, 2026 3:27pm
head to head against clash football helmets fight combat

Rhapsido ph. 3 in MS combines superior safety with strong efficacy

Oct 26, 2026 11:05am
On target clinical trial success bullseye score

Bristol CMO touts more ph. 3 wins for bispecific ADC iza-bren

Oct 26, 2026 3:30am
AstraZeneca

ESMO: AZ, Hutchmed’s Orpathys combo shows post-Tagrisso power

Oct 25, 2026 11:30am
Xia

Akeso CEO looks for more ivonescimab combos after AZ deal

Oct 25, 2026 11:30am
More News

Merck’s sac-TMT posts major PFS benefit in PD-L1-negative NSCLC

Oct 25, 2026 5:15am

ESMO: AstraZeneca pitches own Padcev combos in bladder cancer

Oct 24, 2026 10:30am

ESMO: Amgen’s Imdelltra stages Rasonque-like moment in SCLC

Oct 24, 2026 10:30am

Bayer's Nubeqa eyes wider market after phase 3 win

Oct 24, 2026 8:30am